# Efficacy and safety of different doses of ligelizumab in patients with chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials with GRADE evaluation

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-different-doses-of-ligelizumab-in-patients-with-chronic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lamees Taman,Mohamed Abo Zeid,Kareem Khalefa,Habiba Tariq Saeed,Ahmed Elkelany,Habiba Abdelhameed Elrefaey,Amr M. Abou Elezz |
| Citations | 0 |
| DOI | 10.1007/s00210-025-04775-8 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s00210-025-04775-8.pdf |
| OpenAlex ID | https://openalex.org/W4416307133 |
| PMID | 41251748 |
| Type | review |
| Year | 2025 |

## Paper authors

- [Kareem Khalefa](https://scholariq.org/researchers/kareem-khalefa/)

## Paper primary topic

- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Paper topics

- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Mast cells and histamine](https://scholariq.org/topics/mast-cells-and-histamine/)
- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.